pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PSI): -- Reincorporation in the US Completed -- Interim results from Medidur for DME Study -- Commencement of new Medidur AMD Trial -- Commencement of BrachySil Pancreatic Cancer Dose Ranging Clinical Trial pSivida Corp.

Emory University, CardioMEMS, Alimera Sciences and Proxima Therapeutics are 2006 winners of the Georgia Biomedical Partnership's (GBP) Deal of the Year awards. They will be honored at the GBP's Annual Awards Dinner January 13 at the Grand Hyatt Atlanta.

By Andy Miller, The Atlanta Journal-Constitution Nov. 30--Alimera Sciences, an emerging pharmaceutical company, said Tuesday it has secured $31.8 million in new venture capital -- one of the biggest such financings for a Georgia life sciences company.

pSivida Limited -- Creates one of the world's first bio-nanotech companies with product revenues -- Commercialized products include Vitrasert(R) for CMV retinitis and the recently launched Retisert(TM) for uveitis -- Diversified product pipeline includes Medidur(TM) for diabetic macular edema in Phase III trials -- Existing licensing / development agreements with Bausch & Lomb and Alimera Sciences -- Extensive patent portfolio -- Operating base in Boston, MA biotech hub for further expansion into U.S.